Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial

• Status: Completed
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The object of this study is to evaluate the superiority of aprepitant therapy with a 5HT3-receptor antagonist, dexamethasone and aprepitant compared to standard therapy with a 5HT3-receptor antagonist and dexamethasone for prevention of nausea and vomiting in first course chemotherapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
• Treatments: Aprepitant; BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Fosaprepitant

Criteria

Inclusion Criteria:

• Age: ≥20 years old

• Sex: Not specified

• Patients with colon/rectal cancer who first underwent FOLFOX, XELOX or SOX regimen including oxaliplatin at ≥85 mg/m2 (naive patient), or those who had already started chemotherapy and had nausea of Grade 2 or higher in the last course or an earlier course (non-naive patient).

• Stage: not specified (neoadjuvant/adjuvant chemotherapy, advanced or recurrent type are allowed)

• Combination of molecular targeted therapy: allowable

• Written informed consent for participation in the study.

Exclusion Criteria:

• Severe liver or kidney disease

• Nausea/vomiting within 24 hr prior to chemotherapy.

• Treatment with antiemetics within 24 hr prior to chemotherapy.

• Presence of factors causing nausea/vomiting other than chemotherapy (e.g. brain tumor, gastrointestinal obstruction, active peptic ulcer disease, brain metastasis)

• Presence of a disease precluding 3-day administration of dexamethasone (e.g. uncontrollable diabetes)

• Pregnant or lactating women, women who plan to become pregnant.

• Current treatment with pimozide.

• Any patient judged to be inappropriate for the study by the investigator.